#Sweden #Stockholm #Gags #cancer biomarker #Elypta

Elypta's Revolutionary Cancer Risk Prediction Through Urine Biomarkers

In an innovative advancement in cancer risk assessment, Elypta has unveiled findings from a peer-reviewed study that provides significant insights into how urine biomarkers can predict cancer risk in healthy adults. With the study involving 5,436 adults, researchers have showcased the efficacy of a unique urine profile comprised of three glycosaminoglycan disaccharides (GAGs), aimed at enhancing five-year cancer risk predictions.

The Study Breakdown

The peer-reviewed findings, published in Cancer Epidemiology, Biomarkers & Prevention, suggest that this urine profile can effectively identify individuals at a greater risk of developing cancer. The implications of this finding are profound, moving beyond traditional risk assessment methods that predominantly rely on age and smoking history. According to Karl Bergman, CEO of Elypta, incorporating a biological signal from urine provides crucial data regarding potential cancer risks, particularly in the early stages.

The research team conducted a thorough analysis using 24-hour urine samples from a vast Dutch cohort. They systematically studied individuals who were later diagnosed with cancer compared to a control group that remained cancer-free. The highlighted GAGs, found to influence cancer-related processes, provided a compelling narrative about their role in predicting cancer risk based on dynamic biological changes in the body rather than fixed inherited risks.

Key Findings

The GAG profile, referred to as the GAGome score, stratified participants into different risk categories. Notably, around 13% to 23% of participants fell into a pre-specified high-risk group, which astonishingly accounted for 54% of all cancers diagnosed over the subsequent five years. This group also represented 54% of diagnosed in situ carcinomas, indicating a significant correlation between GAG levels and cancer presence. Conversely, only 17% of individuals who maintained cancer-free status were included in this high-risk category, underscoring the effective predictive capabilities of the GAGome score.

Adding further significance, the GAGome score demonstrated consistent performance across diverse age ranges, notably excelling in cancers without established screening protocols, including pancreatic, kidney, and brain cancers.

Implications for Future Screening

As the landscape of cancer detection evolves, Elypta's findings may reshape how healthcare professionals approach cancer screening and risk assessment. The potential for a urine-based test adds a non-invasive avenue for identifying those most likely to develop cancer, thus directing screening efforts effectively. Importantly, Bergman emphasizes that the methodology relies on only three GAGs, showcasing its potential as a proof of concept that could lead to broader applications of urine biomarkers in the field.

Notably, this study takes a significant step toward exploring more extensive GAG panels and potentially integrating other forms of biological markers, including plasma assessments. According to John Field, a co-author of the study, the results underscore the necessity for independent prospective validation before any clinical implementation is approved.

The Next Steps

In light of these compelling findings, Elypta is poised to pioneer a transformative era in cancer risk detection, leveraging their MIRAM® GAGome Kit designed for meticulous quantification of these urine markers for research purposes.

As researchers and healthcare providers look to improve their strategies in cancer risk stratification, Elypta's pioneering urine biomarker study may very well be the key to unlocking early detection methods that could save lives.

For further inquiries, Karl Bergman can be contacted at email protected] or via their website at [elypta.com.